Conatus's pan-caspase inhibitor in Phase I/II islet cell transplantation/diabetes trial
This article was originally published in Scrip
Executive Summary
Conatus Pharmaceuticals has begun a Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor, for use in enhancing islet cell transplantation.